EpigralQ3 FY24

Epigral Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹947.6P/E: 14.4Market Cap: ₹4.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Epigral Limited expects volume growth driven by new products commissioned in FY23 such as Epichlorohydrin and CPVC Resin.
  • Additional capacity of CPVC Resin (45,000 tons per annum), CPVC compound (35,000 tons per annum), and Chlorotoluenes value chain will be commissioned, targeting growth in FY25 and FY26.
  • Revenue contribution from derivative and specialty segment increased to 42% in nine months FY24 versus 27% in the prior year and is expected to rise further due to future expansions focused on these high-growth products.
  • The company anticipates consistent top-line and bottom-line growth through diversification and multi-product catering to various industries.
  • Long-term demand outlook for the chemical and manufacturing sectors in India remains positive despite short-term pressure and destocking.
  • Capacity utilization is expected to optimize by H1 FY25 for newer capacities like CPVC Resin, contributing to sales growth.

See what Epigral management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • No explicit mention of new fundraising through debt or equity in the call transcript.
  • Current net debt stands at INR 944 crore as of December 31, 2023, increased by INR 81 crore since March 31, 2023, primarily due to INR 323 crore capital expenditure.
  • Management indicated that the current debt level is at its peak and is expected to reduce over time through strong cash flows starting next year.
  • Future capital expenditure planned around INR 300-350 crore annually will be funded by internal accruals and existing cash flows.
  • No plans were disclosed for equity fundraising; debt levels are expected to remain stable or reduce gradually.
  • Free cash flow generated post CapEx will be used partly for debt repayment and dividend distribution.
  • Overall, the company aims to maintain a stable debt level aligned with expansion plans without immediate new debt or equity issuance.

See what Epigral management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Ongoing continuous CapEx planned around INR 300-350 crore annually for growth and expansion.
  • Current CapEx for the year is approximately INR 323 crore, partially funded by internal accruals.
  • New plants and products expected to be commissioned by end of Q4 FY24.
  • Future CapEx includes around INR 200 crore for a Chlorotoluene derivative block (similar 15,000-ton size).
  • Continuous investment in R&D for new chemical chemistries, with a new R&D center established in Ahmedabad.
  • Capacity expansions: CPVC compound capacity with 50% utilization expected by H1 FY25.
  • Company targets 25% ROCE on new projects and aims to maintain CapEx aligned with medium-term revenue/EBITDA guidance, with possible ±10-15% variations.
  • CapEx to turnover ratio for specialty chemical plants expected around 1.4 to 1.5.
  • Maintenance CapEx estimated at 1.5-2% of plant value per year.

Track Epigral — get its next earnings analysis in your feed

How does Epigral rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisEpigral
Rev 3Mar 3

How does Epigral rank in Chemicals & Petrochemicals?

Compare Epigral against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →